Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 25, 2025, titled "Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg".
Press Release Nov 25 2025
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced that it received final approval from the USFDA for Verapamil Hydrochloride Extended-Release Tablets in various strengths. These tablets are intended to help lower high blood pressure and reduce the risk of serious heart issues. The production will take place at Zydus's facility in Baddi, Himachal Pradesh.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
In the deck
Earlier from Zydus Lifesciences
- Press Release Nov 14 2025
- Press Release Nov 13 2025
- Press Release Nov 11 2025
- Press Release Nov 07 2025
- Press Release Nov 06 2025
Later from Zydus Lifesciences
- Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market
- Press Release Nov 26 2025
- Press Release Nov 27 2025
- Press Release Dec 04 2025
- Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences